XML 48 R34.htm IDEA: XBRL DOCUMENT v3.20.2
Interests in subsidiaries
 12 Months Ended
Jun. 30, 2020
Investments accounted for using equity method [abstract]  
Interests in subsidiaries
Note 30. Interests in subsidiaries
The consolidated financial statements incorporate the assets, liabilities and results of the following subsidiaries in accordance with the accounting policy described in note 2:
 
 
  
 
  
Ownership interest
 
Name
  
Principal place of business /
Country of incorporation
  
2020
%
 
 
2019
%
 
Kazia Laboratories Pty Ltd
  
Australia
  
 
100.00
% 
 
 
100.00
% 
Kazia Research Pty Ltd
  
Australia
  
 
100.00
% 
 
 
100.00
% 
Kazia Therapeutics Inc.
  
United States of America
  
 
100.00
% 
 
 
100.00
% 
Glioblast Pty Ltd
  
Australia
  
 
100.00
% 
 
 
100.00
%